Download PDF
Thromb Haemost 1993; 70(06): 0995-0997
DOI: 10.1055/s-0038-1649713
Original Article
Fibrinolysis
Schattauer GmbH Stuttgart

Thrombin Generation Induced by the Intrinsic or Extrinsic Coagulation Pathway is Accelerated by Streptokinase, Independently of Plasminogen

E J P Brommer
The IVVO-TNO, Gaubius Laboratory, Leiden, The Netherlands
,
P Meijer
The IVVO-TNO, Gaubius Laboratory, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 05 April 1993

Accepted after revision 01 July 1993

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Thrombolytic therapy paradoxically induces the formation of fibrinopeptide A, fibrin degradation products and thrombin-antithrombin complexes, indicating thrombin generation. Part of the mechanism of this thrombin generation under the influence of thrombolytic agents was unraveled in this study.

We measured thrombin with a chromogenic substrate at several time intervals after recalcification of citrated plasma which had been preincubated with urokinase, streptokinase, recombinant tissue plasminogen activator (rt-PA) or recombinant singlechain urokinase-type plasminogen activator (rscu-PA). Thrombin generation induced by the addition of thromboplastin together with calcium (extrinsic pathway) was greatly accelerated in the presence of streptokinase (from about 7 to 2 min), and to a lesser extent in the presence of urokinase, rt-PA or rscu-PA. Similar effects were seen after the addition of calcium to the plasma containing the thrombolytic agent and preincubated with partial thromboplastin (intrinsic pathway). Hirudin quenched the conversion of the chromogenic substrate completely, confirming that thrombin was the active enzyme. Aprotinine did not affect the results, and the effect of streptokinase was also observed in plasminogen-depleted plasma. We conclude that streptokinase, and to a lesser extent other thrombolytic agents, activate the prothrombinase complex directly or indirectly through a calcium-dependent mechanism, independently of plasminogen, with a resulting acceleration of thrombin generation.

 

  • References

  • 1 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-620
    PubMedGoogle Scholar
  • 2 Seitz R, Blanke H, Prätorius G, Eckhard StrauerB, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemostas 1988; 59: 541-542
    PubMedGoogle Scholar
  • 3 Rapold HR, Kümmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 980-989
    CrossrefPubMedGoogle Scholar
  • 4 Szcseklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscl Thromb 1992; 12: 548-553
    CrossrefPubMedGoogle Scholar
  • 5 Rapold HJ, de BonoD, Arnold AER, Amout J, De CockF, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Circulation 1992; 85: 928-934
    CrossrefPubMedGoogle Scholar
  • 6 Eisenberg PR, Sherman LA, Tiefenbrunn AJ, Ludbrook PA, Sobel BE, Jaffe AS. Sustained fibrinolysis after administration of t-PA despite short half-life in the circulation. Thromb Haemostas 1987; 57: 35-40
    PubMedGoogle Scholar
  • 7 Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991; 83: 937-944
    CrossrefPubMedGoogle Scholar
  • 8 Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Ginsberg J, Eckhardt T. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 1988; 82: 1700-1707
    CrossrefPubMedGoogle Scholar
  • 9 Mirshahi M, Soria J, Soria C, Samama M, Caen JP. Degradation of fibrinogen by tissue plasminogen activator. Consequences for fibrin polymerization. Thromb Res 1990; (Suppl. 10) 21-26
    PubMedGoogle Scholar
  • 10 Weitz JI, Leslie B. Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin. J Clin Invest 1990; 86: 203-212
    CrossrefPubMedGoogle Scholar
  • 11 Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 19: 1065-1069
    CrossrefPubMedGoogle Scholar
  • 12 Seitz R, Pelzer H, Immel A, Egbring R. Prothrombin activation by thrombolytic agents. Fibrinolysis 1993; 7: 109-115
    PubMedGoogle Scholar
  • 13 Eisenberg PR, Miletich JP, Sobel BE. Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. Fibrinolysis 1991; 5: 217-224
    PubMedGoogle Scholar
  • 14 Brommer EJP, Van BockelJH. Composition and susceptibility to thrombolysis of human arterial thrombi and the influence of their age. Blood Coagul Fibrinol 1992; 3: 717-725
    CrossrefPubMedGoogle Scholar
  • 15 Bachmann F. Plasminogen activators. In: Hemostasis and Thrombosis. Cloman RW, Hirsh J, Marder VJ, Salzman EW. (eds) Philadelphia: Lippincott; 1982: 318-339
    Google Scholar
  • 16 Tiefenbrunn AJ, Robison AK, Kurnik PB, Ludbrook PA, Sobel BE. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1985; 71: 110-116
    CrossrefPubMedGoogle Scholar
  • 17 Verstraete M, Su CAPF, Tanswell P, Feuerer W, Collen D. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemostas 1986; 56: 1-5
    PubMedGoogle Scholar
  • 18 Collen D, Bounameaux H, De CockF, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 73: 511-517
    CrossrefPubMedGoogle Scholar
  • 19 Seifried E, Tanswell P, Ellbrück D, Haerer W, Schmidt A. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemostas 1989; 61: 497-501
    PubMedGoogle Scholar
  • 20 Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986; 56: 09-17
    PubMedGoogle Scholar
  • 21 Aronson DL, Ping Chang, Kessler CM. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 1992; 85: 1706-1712
    CrossrefPubMedGoogle Scholar
  • 22 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemostas 1989; 61: 25-29
    PubMedGoogle Scholar
  • 23 De FouwNJ, Bertina RM, Haverkate F. Activated protein C and fibrinolysis; a link between coagulation and fibrinolysis. In: Fibrinogen, thrombosis, coagulation, and fibrinolysis. Liu CY, Chien S. (eds) New York: Plenum Press; 1991: 235-243
    Google Scholar
  • 24 Römisch J, Ciehl K-H, Reiner G, Pâques E-P. Activated protein C: antithrombotic properties and influence on fibrinolysis in an animal model. Fibrinolysis 1991; 5: 191-196
    PubMedGoogle Scholar